Tarsus Pharmaceuticals Inc (TARS) - Total Liabilities
Based on the latest financial reports, Tarsus Pharmaceuticals Inc (TARS) has total liabilities worth $264.41 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Tarsus Pharmaceuticals Inc (TARS) investment intensity to see how much of total assets are deployed in long-term investments.
Tarsus Pharmaceuticals Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Tarsus Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Tarsus Pharmaceuticals Inc's balance sheet.
Tarsus Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Tarsus Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BBVA Banco Frances SA
BA:BBAR
|
Argentina | AR$21.87 Trillion |
|
Life360, Inc. Common Stock
NASDAQ:LIF
|
USA | $438.49 Million |
|
Legend Biotech Corp
NASDAQ:LEGN
|
USA | $521.32 Million |
|
GZ Port
SHG:601228
|
China | CN¥29.16 Billion |
|
Viohalco S.A
BR:VIO
|
Belgium | €-2.36 Billion |
|
Firefly Aerospace Inc. Common Stock
NASDAQ:FLY
|
USA | $416.30 Million |
|
Grupa KĘTY SA
WAR:KTY
|
Poland | zł2.72 Billion |
|
Inter Cars S.A.
WAR:CAR
|
Poland | zł7.10 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Tarsus Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Tarsus Pharmaceuticals Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.76 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tarsus Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tarsus Pharmaceuticals Inc (2018–2025)
The table below shows the annual total liabilities of Tarsus Pharmaceuticals Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $218.73 Million | +43.47% |
| 2024-12-31 | $152.46 Million | +122.56% |
| 2023-12-31 | $68.50 Million | +95.93% |
| 2022-12-31 | $34.96 Million | +187.12% |
| 2021-12-31 | $12.18 Million | +103.22% |
| 2020-12-31 | $5.99 Million | -90.68% |
| 2019-12-31 | $64.32 Million | +1618.43% |
| 2018-12-31 | $3.74 Million | -- |
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as we… Read more